Efforts to lower drug prices have led to a steady increase in FDA approvals of abbreviated new drug applications (ANDAs), including first-time generics. With 73 approvals currently, and a projected 109 by the end of the year, the number of first-time generic approvals has risen 49% since 2016. When looking at approvals of all abbreviated new drug applications, including tentative approvals, the FDA has given its seal to nearly 28% more than it did three years ago.